Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ajooni Biotech's Enterprise Value is ₹830 Mil.
Ajooni Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil. Therefore, Ajooni Biotech's EV-to-FCF for today is .
The historical rank and industry rank for Ajooni Biotech's EV-to-FCF or its related term are showing as below:
NSE:AJOONI'
s EV-to-FCF Range Over the Past 10 Years
Min: -3.49 Med: 0 Max: 0
Current: -3.49
NSE:AJOONI's EV-to-FCF is ranked worse than 100% of 1179
companies
in the Consumer Packaged Goods industry
Industry Median: 16.07
vs NSE:AJOONI: -3.49
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ajooni Biotech's PE Ratio (TTM) for today is calculated as:
Ajooni Biotech's share price for today is ₹3.86.
Ajooni Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.200.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ajooni Biotech EV-to-FCF Related Terms
Ajooni Biotech EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Ajooni Biotech's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Ajooni Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ajooni Biotech EV-to-FCF vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Ajooni Biotech's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Ajooni Biotech's EV-to-FCF falls into.
Ajooni Biotech's current Enterprise Value is ₹830 Mil.
Ajooni Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Ajooni Biotech (NSE:AJOONI) Overvalued in 2026?
Based on GuruFocus' analysis, Ajooni Biotech stock appears to be undervalued.
The current stock price of ₹3.86 is trading 38.3% below its estimated GF Value™ of ₹6.26.
GuruFocus considers Ajooni Biotech to be Possible Value Trap.
Key valuation signals for NSE:AJOONI:
EV-to-FCF:
GF Value™: ₹6.26 vs. price of ₹3.86 (38.3% below fair value)
No single metric tells the full story. See the NSE:AJOONI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ajooni Biotech Ltd is engaged in providing animal health care solutions dedicated to improving the productivity of Dairy farmers and sustainably increasing livestock yields. The company's products of cattle feed include Gold Pashu Aahar, Buff Plus, 3 Star, 4 Star, Calf Starter, & Transition Plus, and its feed supplements include Calvit, Batisa, Liv, Min, and other products. It derives majority portion of the revenue from the manufacturing of cattle feed. The company operates only in India.
64GF Score
Get the complete analysis for NSE:AJOONI
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AJOONI has been successfully added to your 
